Logo

PLRZ

Polyrizon Ltd.

PLRZ

Polyrizon Ltd. • NASDAQ
$3.22 ▲ 516.86% (+2.70)
Market Cap $19.29 M
52w High $9600.00
52w Low $2.95
Dividend Yield 0%
P/E -16.1
Volume 127.70K
Outstanding Shares 5.99M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $-1.242K $-88.5 0% $-0.061 $-1.148K
Q1-2025 $0 $-1.242K ▼ $-88.5 ▲ 0% $-0.061 ▲ $-1.148K ▲
Q4-2024 $0 $838K ▲ $-957K ▼ 0% $-0.23 ▲ $-838K ▼
Q3-2024 $0 $-477.5 ▼ $-478.5 ▲ 0% $-36.3 ▼ $-419 ▲
Q2-2024 $0 $346K $-588K 0% $-0.14 $-346K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $15.828M $18.739M $364K $18.375M
Q1-2025 $15.828M ▲ $18.739M ▲ $364K ▲ $18.375M ▲
Q4-2024 $2.554M $5.547M $261K $5.286M
Q3-2024 $2.554M ▲ $5.547M ▲ $261K ▼ $5.286M ▲
Q2-2024 $23K $586K $612K $222K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-88.5 $-1.821M ▼ $-2K ▼ $15.097M ▲ $13.274M ▲ $-911.5
Q1-2025 $-88.5 ▲ $-910.5 ▲ $0 ▼ $7.548K ▼ $0 ▼ $-911.5 ▲
Q4-2024 $-957K ▼ $-810K ▼ $29K ▲ $3.312M ▲ $2.531M ▲ $-810K ▼
Q3-2024 $-478.5 ▲ $-405 ▲ $14.5 ▲ $1.656K ▼ $0 ▼ $-405 ▲
Q2-2024 $-588K $-337K $0 $356K $19K $-337K

Five-Year Company Overview

Income Statement

Income Statement Polyrizon is essentially a pure research-stage biotech right now, with no meaningful revenue and no established profit engine. Results are driven almost entirely by development and corporate costs, not by product sales. The earnings per share history looks noisy and not very informative yet, likely reflecting small-company accounting items or one-time effects rather than a stable business trend. Overall, the income statement does not yet tell a story of an operating business; it tells the story of a company still in the build-out phase, before commercialization.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of assets and equity and no reported debt. This points to a tiny company in financial terms, with limited resources but also no leverage risk at this stage. The lack of debt reduces pressure from lenders, but the small asset base also means less buffer if timelines slip or costs rise. In practice, this is a balance sheet that depends heavily on the company’s continued ability to issue new shares or secure partnerships to fund its plans.

Cash Flow

Cash Flow Reported cash flow figures are effectively flat, which is typical of very early or very small companies but not very informative. In reality, a research-stage biotech like this is almost certainly consuming cash for R&D and overhead, funded by equity raises rather than by operations. With no operating cash inflow from products yet, the key cash-flow question is not efficiency but funding visibility: how reliably the company can bring in fresh capital until products reach the market, if they do.

Competitive Edge

Competitive Edge Competitively, Polyrizon is trying to differentiate itself in a crowded healthcare space through a specialized intranasal hydrogel platform. The “biological mask” concept for allergy and viral protection, plus targeted nose-to-brain delivery for serious neurological conditions, gives the company a distinctive technical story. Its edge rests on platform versatility, drug-free barrier products, and potential advantages in brain-targeted delivery. However, it is still pre-commercial, faces competition from established nasal sprays and large pharma players, and has not yet proven that its scientific advantages will translate into market share or pricing power.

Innovation and R&D

Innovation and R&D Innovation is the core of the company. Polyrizon’s twin platforms—Capture and Contain for protective barriers and Trap and Target for intranasal drug delivery—support a pipeline that spans consumer-like allergy and viral blockers as well as high-stakes emergency treatments such as intranasal naloxone and seizure rescue therapies. Early lab and preclinical results are encouraging on paper, and the company is preparing for its first clinical trial of its allergy blocker. Still, everything is at an early, high-uncertainty stage: safety in humans, real-world effectiveness, regulatory acceptance, and scalability remain to be proven, and timelines are inherently long for biotech development.

Summary

Polyrizon is a very early-stage, pre-revenue biotech with a tiny financial footprint and a science-heavy story built around novel intranasal hydrogel platforms. Financial statements offer little comfort in terms of revenue or cash generation; the company’s future hinges on successful clinical development, constructive feedback from regulators, and the ability to fund ongoing R&D. Its technology and pipeline are differentiated and potentially wide-reaching, but also unproven in the clinic or the marketplace. The overall picture is one of high uncertainty: significant scientific and regulatory upside if things work as hoped, set against meaningful execution and funding risks typical of small, development-stage biotech firms.

NEWS

November 6, 2025 · 8:55 AM UTC

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Read more

October 6, 2025 · 8:21 AM UTC

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Read more

September 19, 2025 · 8:15 AM UTC

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Read more

September 12, 2025 · 7:26 AM UTC

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Read more